Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation |
| |
| Authors: | Voravit Ratanatharathorn,Brent Logan,Dan Wang,Mary Horowitz,Joseph P. Uberti,Olle Ringden,Robert Peter Gale,Hanna Khoury,Mukta Arora,Stephen Spellman,Corey Cutler,Joseph Antin,Martin Bornhaü ser,Gregory Hale,Leo Verdonck,Mitchell Cairo,Vikas Gupta, Steven Pavletic,for the Center for International Blood Marrow Transplant Research ,Milwaukee,WI,USA |
| |
| Affiliation: | Blood and Marrow Transplantation Program, Karmanos Cancer Institute, Wayne State University, Detroit, MI;, CIBMTR, Milwaukee, WI;, CIBMTR, Minneapolis, MN, USA;, Department of Clinical Immunology, Karolinska University Hospital, Stockholm, Sweden;, Celgene, Summit, NJ;, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA;, University of Minnesota, Minneapolis, MN;, Dana-Farber Cancer Institute, Boston, MA, USA;, Institute of Immunology, Technische Universität Dresden, Dresden, Germany;, St Jude Children's Research Hospital, Memphis, TN, USA;, University Medical Centre Utrecht, Utrecht, The Netherlands;, Morgan Stanley Children's Hospital of New York-Presbyterian, Columbia University, New York, NY, USA;, Princess Margaret Hospital, Toronto, ON, Canada;, and National Institute of Health, Bethesda, MD, USA |
| |
| Abstract: | Prior therapy with rituximab might attenuate disparate histocompatibility antigen presentation by B cells, thus decreased the risk of acute graft-versus-host disease (GVHD) and improved survival. We tested this hypothesis by comparing the outcomes of 435 B-cell lymphoma patients who received allogeneic transplantation from 1999 to 2004 in the Center for International Blood and Marrow Transplant Research database: 179 subjects who received rituximab within 6 months prior to transplantation (RTX cohort) and 256 subjects who did not receive RTX within 6 months prior to transplantation (No-RTX cohort). The RTX cohort had a significantly lower incidence of treatment-related mortality (TRM) [relative risk (RR) = 0·68; 95% confidence interval (CI), 0·47–1·0; P = 0·05], lower acute grade II–IV (RR = 0·72; 95% CI, 0·53–0·97; P = 0·03) and III–IV GVHD (RR = 0·55; 95% CI, 0·34–0·91; P = 0·02). There was no difference in the risk of chronic GVHD, disease progression or relapse. Progression-free survival (PFS) (RR = 0·68; 95% CI 0·50–0·92; P = 0·01) and overall survival (OS) (RR = 0·63; 95% CI, 0·46–0·86; P = 0·004) were significantly better in the RTX cohort. Prior RTX therapy correlated with less acute GVHD, similar chronic GVHD, less TRM, better PFS and OS. |
| |
| Keywords: | rituximab lymphoma graft-versus-host disease allogeneic transplantation |
|
|
